Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Share-based Compensation (2016 - 2025)

Spyre Therapeutics (SYRE) has disclosed Share-based Compensation for 11 consecutive years, with $9.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation rose 6.46% year-over-year to $9.8 million, compared with a TTM value of $37.6 million through Dec 2025, down 16.1%, and an annual FY2025 reading of $37.6 million, down 16.1% over the prior year.
  • Share-based Compensation was $9.8 million for Q4 2025 at Spyre Therapeutics, up from $9.6 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $17.3 million in Q4 2023 and bottomed at $1.4 million in Q4 2022.
  • Average Share-based Compensation over 5 years is $6.2 million, with a median of $3.5 million recorded in 2021.
  • The sharpest move saw Share-based Compensation surged 1110.23% in 2023, then tumbled 46.64% in 2024.
  • Year by year, Share-based Compensation stood at $2.1 million in 2021, then tumbled by 31.85% to $1.4 million in 2022, then soared by 1110.23% to $17.3 million in 2023, then plummeted by 46.64% to $9.2 million in 2024, then increased by 6.46% to $9.8 million in 2025.
  • Business Quant data shows Share-based Compensation for SYRE at $9.8 million in Q4 2025, $9.6 million in Q3 2025, and $9.4 million in Q2 2025.